Medical management of high-grade astrocytoma: Current and emerging therapies

Seminars in Oncology

Volumn 41, Issue 4, 2014, Pages 511-522

  Johnson, Derek R ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYTOTOXIC AGENT; TEMOZOLOMIDE; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; NEW DRUG;

ANTIANGIOGENIC THERAPY; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; TREATMENT INDICATION; TUMOR GROWTH; BRAIN NEOPLASMS; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TRENDS; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASM GRADING; STANDARD OF CARE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84906769839     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.06.010     Document Type: Article

References (83)

1. R. Stupp, M.E. Hegi, and W.P. Mason et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
2. M.D. Walker, S.B. Green, and D.P. Byar et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1980 1323 1329
3. L. Souhami, W. Seiferheld, and D. Brachman et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol Int J Radiat Oncol Biol Phys 60 2004 853 860
4. M.M. Fitzek, A.F. Thornton, and J.D. Rabinov et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial J Neurosurg 91 1999 251 260
5. R. Stupp, W.P. Mason, and M.J. van den Bent et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
6. L.A. Stewart Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 2002 1011 1018
7. M.E. Hegi, A.C. Diserens, and T. Gorlia et al. MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
8. M.D. Groves, and A.B. Plummer Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment Continuum 18 2012 421 425
9. M.R. Gilbert, M. Wang, and K.D. Aldape et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial J Clin Oncol 31 2013 4085 4091
10. F.Y. De Vos, J.M. Gijtenbeek, and C.P. Bleeker-Rovers et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas Crit Rev Oncol Hematol 85 2013 373 382
11. O.L. Chinot, W. Wick, and W. Mason et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma N Engl J Med 370 2014 709 722
12. M.R. Gilbert, J.J. Dignam, and T.S. Armstrong et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 2014 699 708
13. E.P. Sulman Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM) [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 LBA2010
14. N. Laperriere, M. Weller, and R. Stupp et al. Optimal management of elderly patients with glioblastoma Cancer Treat Rev 39 2013 350 357
15. W. Roa, P.M. Brasher, and G. Bauman et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial J Clin Oncol 22 2004 1583 1588
16. A. Malmstrom, B.H. Gronberg, and C. Marosi et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Lancet Oncol 13 2012 916 926
17. W. Wick, M. Platten, and C. Meisner et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 2012 707 715
18. NCIC Clinical Trials Group. Radiation therapy with or without temozolomide in treating older patients with newly diagnosed glioblastoma multiforme. Bethesda (MD): National Library of Medicine (US). 2000-Available from: clinicaltrials.gov.
19. M. Westphal, D.C. Hilt, and E. Bortey et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma Neurooncology 5 2003 79 88
20. M.J. McGirt, K.D. Than, and J.D. Weingart et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme J Neurosurg 110 2009 583 588
21. M. Salvati, A. D'Elia, and A. Frati et al. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis J Neurosurg Sci 55 2011 1 6
22. P. Miglierini, M. Bouchekoua, and B. Rousseau et al. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity Clin Neurol Neurosurg 114 2012 1222 1225
23. G. Noel, R. Schott, and S. Froelich et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas Int J Radiat Oncol Biol Phys 82 2012 749 755
24. D. Brandsma, and M.J. van den Bent Pseudoprogression and pseudoresponse in the treatment of gliomas Curr Opin Neurol 22 2009 633 638
25. P.Y. Wen, D.R. Macdonald, and D.A. Reardon et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J Clin Oncol 28 2010 1963 1972
26. B. Neyns, A. Tosoni, and W.J. Hwu et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects Cancer 116 2010 2868 2877
27. H.M. Strik, C. Marosi, and B. Kaina et al. Temozolomide dosing regimens for glioma patients Curr Neurol Neurosci Rep 12 2012 286 293
28. J.R. Perry, K. Belanger, and W.P. Mason et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study J Clin Oncol 28 2010 2051 2057
29. T.T. Batchelor, P. Mulholland, and B. Neyns et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma J Clin Oncol 31 2013 3212 3218
30. M. Van den Bent, W. Taal, H.M. Oosterkamp, and A.M.E. Walenkamp et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study J Clin Oncol 13 suppl; abstr 2001 2013
31. M.W. Pitz, M. Lipson, and B. Hosseini et al. Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma Curr Oncol 19 2012 308 314
32. A.P. Kyritsis, W.K. Yung, and K.A. Jaeckle et al. Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas Neurosurgery 39 1996 921 926
33. T.N. Kreisl, L. Kim, and K. Moore et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
34. H.S. Friedman, M.D. Prados, and P.Y. Wen et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
35. D.R. Johnson, H.E. Leeper, and J.H. Uhm Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis Cancer 119 2013 3489 3495
36. J.J. Raizer, S. Grimm, and M.C. Chamberlain et al. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas Cancer 116 2010 5297 5305
37. J.F. de Groot High-dose antiangiogenic therapy for glioblastoma: less may be more? Clin Cancer Res 17 2011 6109 6111
38. W. Taal, H.M. Oosterkamp, and A.M.E. Walenkamp et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 2001
39. European Organization for Research and Treatment of Cancer. Bevacizumab and Lomustine for Recurrent GBM, ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda, MD
40. K. Maree Field A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET) [abstract] J Clin Oncol 31 2013 2017
41. V. Ranpura, B. Pulipati, and D. Chu et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis Am J Hypertens 23 2010 460 468
42. Y. Narita Drug review: safety and efficacy of bevacizumab for glioblastoma and other brain tumors Jpn J Clin Oncol 43 2013 587 595
43. V. Ranpura, S. Hapani, and S. Wu Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis JAMA 305 2011 487 494
44. A.D. Norden, J. Bartolomeo, and S. Tanaka et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients J Neurooncol 106 2012 121 125
45. D.A. Reardon, J.E. Herndon 2nd, and K.B. Peters et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients Br J Cancer 107 2012 1481 1487
46. S.E. Combs, S. Gutwein, and C. Thilmann et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme J Neuro-oncol 74 2005 167 171
47. T. Hundsberger, D. Brugge, and P.M. Putora et al. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas J Neurooncol 112 2013 133 139
48. A.M. Davies, U. Weinberg, and Y. Palti Tumor treating fields: a new frontier in cancer therapy Ann N Y Acad Sci 1291 2013 86 95
49. R. Stupp, E.T. Wong, and A.A. Kanner et al. NovoTTF-100A versus physicians choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality Eur J Cancer 48 2012 2192 2202
50. Novocure Ltd. Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM) ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda, MD
51. G. Cairncross, M. Wang, and E. Shaw et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402 J Clin Oncol 31 2013 337 343
52. M.J. van den Bent, A.A. Brandes, and M.J. Taphoorn et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 J Clin Oncol 31 2013 344 350
53. J.G. Cairncross, M. Wang, and R.B. Jenkins et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH J Clin Oncol 32 2014 783 790
54. National Comprehensive Cancer Network. Central nervous system cancers. Version 2.2013.
55. S. Scoccianti, S.M. Magrini, and U. Ricardi et al. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology) Neurooncology 14 2012 798 807
56. W. Wick, C. Hartmann, and C. Engel et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide J Clin Oncol 27 2009 5874 5880
57. J.A. Quinn, S.X. Jiang, and D.A. Reardon et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J Clin Oncol 27 2009 1262 1267
58. A.J. Chalmers The potential role and application of PARP inhibitors in cancer treatment Br Med Bull 89 2009 23 40
59. L.R. Kleinberg, J.G. Supko, and T. Mikkelsen et al. Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 2065
60. J.K. Burkhardt, H.A. Riina, and B.J. Shin et al. Intra-arterial chemotherapy for malignant gliomas: a critical analysis Interv Neuroradiol 17 2011 286 295
61. D. Fortin, A. Desjardins, and A. Benko et al. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience Cancer 103 2005 2606 2615
62. A.I. Qureshi, M.F. Suri, and J. Khan et al. Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures J Neurooncology 51 2001 151 158
63. F. Imbesi, E. Marchioni, and E. Benericetti et al. A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas Anticancer Res 26 2006 553 558
64. M. Kochii, I. Kitamura, and T. Goto et al. Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma J Neurooncol 49 2000 63 70
65. A. Silvani, M. Eoli, and A. Salmaggi et al. Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma Neurol Sci 23 2002 219 224
66. L.B. Nabors, T. Mikkelsen, and S.S. Rosenfeld et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma J Clin Oncol 25 2007 1651 1657
67. R. Stupp, M.E. Hegi, and B. Neyns et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma J Clin Oncol 28 2010 2712 2718
68. L.B. Nabors, T. Mikkelsen, and M.E. Hegi et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) Cancer 118 2012 5601 5607
69. 6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study [abstract] J Clin Oncol (Meeting Abstracts) 31 2013 LBA2009
70. 6-methylguanine-DNA-methyltranferase (MGMT) gene promoter: key results of the open-label, controlled, randomized phase II CORE study [abstract] Neuro-Oncology (Meeting Abstracts) 15 2013 (abstract MR-021)
71. M.D. Groves, V.K. Puduvalli, and M.R. Gilbert et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme Br J Cancer 01 2009 615 620
72. W.K. Yung, M. Prados, and V.A. Levin et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study J Clin Oncol 9 1991 1945 1949
73. ®-L] to treat newly diagnosed GBM brain cancer ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda, MD
74. Celldex Therapeutics C. Phase III study of rindopepimut/GM-CSF in patients with newly diagnosed glioblastoma (ACT IV) ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda, MD
75. C.A. Del Vecchio, and A.J. Wong Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme Curr Opin Mol Ther 12 2010 741 754
76. A. Parsa, C. Crane, and S. Han et al. Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): results of a phase II multicenter clinical trial with immunological assessments [abstracts] J Clin Oncol (Meeting Abstracts) 29 2011 2565
77. European Organization for Research and Treatment of Cancer. Radiation therapy with or without temozolomide in treating patients with anaplastic glioma. ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda, MD
78. Alliance for Clinical Trials in Oncology Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma. ClinicalTrials.gov [Internet] 2000 National Library of Medicine (US) Bethesda, MD
79. H.S. Phillips, S. Kharbanda, and R. Chen et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 2006 157 173
80. R.G. Verhaak, K.A. Hoadley, and E. Purdom et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
81. E. Galanis, W. Wu, and T. Cloughesy et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group Lancet Oncol 13 2012 e196 e204
82. E. Galanis, W. Wu, and J. Sarkaria et al. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments Curr Oncol Rep 13 2011 42 49
83. D.R. Johnson, and E. Galanis Incorporation of prognostic and predictive factors into glioma clinical trials Curr Oncol Rep 15 2013 56 63